Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.

Trial Details

NCT ID
NCT05450965
Phase
PHASE2
Sponsor
University of Maryland, Baltimore
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Onvansertib
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Patients must have histologically or cytologically confirmed small cell lung cancer
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter t…
  • Patient must have failed or found to be intolerant of standard frontline platinum-based regimens and not more than two lines of cytotoxic chemother…
  • Adult patients with age \>18 years. Because no dosing or adverse event data are currently available on the use of arsenic trioxide in patients \<18…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →